Pharmacy Fusion - Using genetic factors to determine successful drugs and doses
Dean Walter Fitzgerald welcomes ISU Associate Professor of Biomedical and Pharmaceutical Sciences Dr. Jared Barrott for this episode of Pharmacy Fusion. They talk about how pharmacogenomics helps doctors, pharmacists, and researchers predict success of medication therapy based on a patient’s genetics. Dr. Barrott discusses his research and provides predictions for the future of genetics and pharmacogenomics.
Dr. Jared Barrot biography:
Dr. Barrott focuses on cancer pharmacology by understanding the biology behind cancer initiation and progression. He graduated from Duke University with a PhD degree in Pharmacology and Cancer Biology and trained at the Huntsman Cancer Institute in Salt Lake City. Originally from Tennessee, Dr. Barrott loves the mountains and outdoor activities that Idaho offers. The lab uses genetically engineered mouse models (GEMMs) to test novel therapies that target cancer’s vulnerabilities. Our interests include cellular high throughput drug screening, cellular biology, genetics, pharmacogenetics, research design, and data analysis. Some infectious diseases, especially in the field of virology. Cancer biology and pharmacology.
In the lab, we focus on rare sarcomas that typically arise in pediatric patients. These cancers of the connective tissues are commonly driven by chromosomal translocations, which are powerful epigenetic reprogrammers that can transform normal muscle, cartilage, and bone cells to become cancerous. I use biochemistry and genetics to understand the events that surround cellular transformation in order to better understand where the cancer cell is vulnerable. Using targeted therapies we aim to reduce the primary tumor and eliminate the metastatic burden while doing the least harm to normal tissues. I have three mouse models of sarcoma in which I can test various anti-cancer therapies to provide a rationale for clinical human testing. The three sarcomas that we study are synovial sarcoma, alveolar soft part sarcoma, and osteosarcoma. In these transgenic mice, we can control the spatial and temporal expression of oncogenes that drive the sarcomas.